Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb long-term extension study of daratumumab in multiple myeloma
CTR20233035Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with serious adverse events, Number of participants with adverse events of special interest and 2 more. Started Nov 2023; status: active.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20233035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233035.